Inverness expands with HemoSense deal
This article was originally published in Clinica
Inverness Medical Innovations (Waltham, Massachusetts) has entered into a definitive agreement to purchase point-of-care diagnostic company HemoSense. The all-stock deal, which is subject to shareholder approval and is expected to close in the fourth quarter of 2007, will see each holder of a HemoSense share receive 0.274192 shares of Inverness common stock - an approximate 38% premium over the average trading prices of both companies for the last five trading days.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.